TN2010000566A1 - Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs - Google Patents
Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugsInfo
- Publication number
- TN2010000566A1 TN2010000566A1 TNP2010000566A TN2010000566A TN2010000566A1 TN 2010000566 A1 TN2010000566 A1 TN 2010000566A1 TN P2010000566 A TNP2010000566 A TN P2010000566A TN 2010000566 A TN2010000566 A TN 2010000566A TN 2010000566 A1 TN2010000566 A1 TN 2010000566A1
- Authority
- TN
- Tunisia
- Prior art keywords
- ophtalmologic
- retinoprotective
- neuroprotective
- folic acid
- medicine
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 title abstract 4
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 title abstract 2
- 229960000304 folic acid Drugs 0.000 title abstract 2
- 235000019152 folic acid Nutrition 0.000 title abstract 2
- 239000011724 folic acid Substances 0.000 title abstract 2
- 230000000324 neuroprotective effect Effects 0.000 title abstract 2
- 229960003401 ramipril Drugs 0.000 title abstract 2
- 230000003289 retinoprotective effect Effects 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title 1
- 230000001681 protective effect Effects 0.000 title 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 206010046851 Uveitis Diseases 0.000 abstract 1
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 208000001491 myopia Diseases 0.000 abstract 1
- 230000004379 myopia Effects 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 201000010041 presbyopia Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 abstract 1
- KEDYTOTWMPBSLG-HILJTLORSA-N ramiprilat Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)C(O)=O)CC1=CC=CC=C1 KEDYTOTWMPBSLG-HILJTLORSA-N 0.000 abstract 1
- 229960002231 ramiprilat Drugs 0.000 abstract 1
- 210000001525 retina Anatomy 0.000 abstract 1
- 230000004304 visual acuity Effects 0.000 abstract 1
- 230000000007 visual effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TNP2010000566A TN2010000566A1 (en) | 2010-12-03 | 2010-12-03 | Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs |
EP11724029.1A EP2646010B1 (fr) | 2010-12-03 | 2011-05-06 | Combinaison acide folique - ramipril : compositions ophtalmologiques cellulo-protectrices, neuroprotectrices et rétinoprotectrices |
JP2013541436A JP5897592B2 (ja) | 2010-12-03 | 2011-05-06 | 葉酸−ラミプリルの組合せ:細胞保護性、神経保護性、および網膜保護性の眼科用組成物 |
AU2011334617A AU2011334617B2 (en) | 2010-12-03 | 2011-05-06 | Folic acid - Ramipril combination: cellprotective, neuroprotective and retinoprotective ophtalmologic compositions |
CN201180066768.3A CN103338758B (zh) | 2010-12-03 | 2011-05-06 | 叶酸‑雷米普利组合:具细胞保护性、神经保护性及视网膜保护性的眼科组合物 |
RU2013125146/15A RU2602738C2 (ru) | 2010-12-03 | 2011-05-06 | Комбинация фолиевой кислоты и рамиприла: цитопротекторные, нейропротекторные и ретинопротекторные офтальмологические композиции |
US13/991,286 US20130317036A1 (en) | 2010-12-03 | 2011-05-06 | Folic acid - ramipril combination: cellprotective, neuroprotective and retinoprotective ophtalmologic compositions |
CA2819628A CA2819628C (fr) | 2010-12-03 | 2011-05-06 | Combinaison acide folique - ramipril : compositions ophtalmologiques cellulo-protectrices, neuroprotectrices et retinoprotectrices |
PCT/IB2011/000960 WO2012073077A1 (fr) | 2010-12-03 | 2011-05-06 | Combinaison acide folique - ramipril : compositions ophtalmologiques cellulo-protectrices, neuroprotectrices et rétinoprotectrices |
ES11724029T ES2770410T3 (es) | 2010-12-03 | 2011-05-06 | Combinación de ácido fólico - ramiprilo: composiciones oftalmológicas celuloprotectoras, neuroprotectoras y retinoprotectoras |
PL11724029T PL2646010T3 (pl) | 2010-12-03 | 2011-05-06 | Kombinacja kwas foliowy-ramipryl: kompozycje okulistyczne chroniące komórki, neuroprotekcyjne i retinoprotekcyjne |
ZA2013/04026A ZA201304026B (en) | 2010-12-03 | 2013-05-31 | Folic acid-ramipril combination:cellprotective, neuroprotective and retinoprotective ophtalmologic compositions |
US14/599,223 US20150133455A1 (en) | 2010-12-03 | 2015-01-16 | Folic acid – ramipril combination: cell protective, neuroprotective and retinoprotective ophtalmoligic compositions |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TNP2010000566A TN2010000566A1 (en) | 2010-12-03 | 2010-12-03 | Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs |
Publications (1)
Publication Number | Publication Date |
---|---|
TN2010000566A1 true TN2010000566A1 (en) | 2012-05-24 |
Family
ID=54696113
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNP2010000566A TN2010000566A1 (en) | 2010-12-03 | 2010-12-03 | Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs |
Country Status (12)
Country | Link |
---|---|
US (2) | US20130317036A1 (fr) |
EP (1) | EP2646010B1 (fr) |
JP (1) | JP5897592B2 (fr) |
CN (1) | CN103338758B (fr) |
AU (1) | AU2011334617B2 (fr) |
CA (1) | CA2819628C (fr) |
ES (1) | ES2770410T3 (fr) |
PL (1) | PL2646010T3 (fr) |
RU (1) | RU2602738C2 (fr) |
TN (1) | TN2010000566A1 (fr) |
WO (1) | WO2012073077A1 (fr) |
ZA (1) | ZA201304026B (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TN2010000251A1 (fr) * | 2010-06-03 | 2011-11-11 | Rekik Raouf | N-acetyl-dl-leucine medicament neuro et retino protecteur |
ES2715296T3 (es) | 2011-09-20 | 2019-06-03 | Allergan Inc | Composiciones y métodos para tratar presbicia, hipermetropía leve y astigmatismo irregular |
TN2016000259A1 (en) | 2016-06-27 | 2017-10-06 | Rekik Raouf | Salbutamol (albuterol) eye protective medicament. |
AU2017308865B2 (en) * | 2016-08-11 | 2023-04-13 | Intrabio Limited | Therapeutic agents for neurodegenerative diseases |
CN108452309B (zh) * | 2018-03-05 | 2019-08-23 | 佳木斯大学附属第一医院 | 一种用于预防或治疗视神经炎的药物组合物及其制备方法 |
EP3616700A1 (fr) * | 2018-08-29 | 2020-03-04 | Aprofol AG | Préparations de folate pour le traitement des maladies des yeux |
RU2717343C1 (ru) * | 2019-03-01 | 2020-03-23 | Евгений Владимирович Плотников | Средство, обладающее цитопротекторным действием |
CN112933235A (zh) * | 2021-04-07 | 2021-06-11 | 北京蛋白质组研究中心 | 靶向soat1蛋白的化合物在制备预防和/或治疗肝癌药物中的应用 |
CN117561065A (zh) * | 2021-06-24 | 2024-02-13 | 连云港金康和信药业有限公司 | 叶酸类衍生物在制备治疗隐形眼镜不适及干眼症药物的应用 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5804603A (en) | 1993-11-26 | 1998-09-08 | National Science Council | Synthesized β-adrenergic blockers derivatives of guaiacol |
US6417196B1 (en) * | 1998-06-05 | 2002-07-09 | Warner-Lambert Company | Stabilization of quinapril using magnesium oxide |
US6207190B1 (en) * | 1998-08-13 | 2001-03-27 | Chronorx, Llc | Dosage forms for the treatment of the chronic glaucomas |
ES2324200T3 (es) * | 1999-06-16 | 2009-08-03 | Rekik, Elyes Ben Mohamed Raouf | Medicamentos oftalmologicos retino-protectores, que comprenden ramipril o ramiprilato. |
US7335803B2 (en) | 2001-10-19 | 2008-02-26 | Allergan, Inc. | Methods and compositions for modulating alpha adrenergic receptor activity |
US6583152B2 (en) * | 2001-04-30 | 2003-06-24 | Dexgen Pharmaceuticals, Inc. | Composition for reducing the risk or progression of cardiovascular diseases |
JP2005503378A (ja) * | 2001-08-06 | 2005-02-03 | ジエノメツド・エル・エル・シー | Aceの過剰に関連する疾患の治療方法及び組成物 |
US6576256B2 (en) * | 2001-08-28 | 2003-06-10 | The Brigham And Women's Hospital, Inc. | Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
US20030099724A1 (en) * | 2001-11-16 | 2003-05-29 | Turner Oliver E. | Compounds for prevention of diabetic retinopathy |
US7091232B2 (en) | 2002-05-21 | 2006-08-15 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
US7351739B2 (en) * | 2004-04-30 | 2008-04-01 | Wellgen, Inc. | Bioactive compounds and methods of uses thereof |
US20060035864A1 (en) * | 2004-08-10 | 2006-02-16 | Friesen Albert D | Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders |
WO2006085128A1 (fr) * | 2005-02-09 | 2006-08-17 | Wockhardt Limited | Compositions pour le traitement de maladies cardio-vasculaires |
CN101263146B (zh) * | 2005-07-27 | 2012-12-05 | 艾其林医药公司 | 抗感染试剂8-甲氧基-9h-异噻唑并[5,4-b]喹啉-3,4-二酮及相关化合物 |
ES2300188B1 (es) * | 2006-05-24 | 2009-05-01 | Ferrer Internacional, S.A. | Comprimido bicapa para la prevencion de los accidentes cardiovasculares. |
CN101176788B (zh) * | 2006-11-11 | 2011-06-15 | 深圳奥萨医药有限公司 | Ace抑制剂/利尿剂/叶酸联用的药物组合物及其用途 |
WO2008132756A1 (fr) * | 2007-05-01 | 2008-11-06 | Lupin Limited | Compositions pharmaceutiques stables de ramipril |
CN101396561A (zh) * | 2007-09-28 | 2009-04-01 | 北京华安佛医药研究中心有限公司 | 含有acei的组合物在制备治疗高同型半胱氨酸血症损伤及其相关疾病的药物中的用途 |
CN101590084B (zh) * | 2008-05-29 | 2012-12-05 | 北京奥萨医药研究中心有限公司 | 含有血管紧张素转化酶抑制剂、b族维生素和银杏叶提取物的药物组合物 |
CN101322743A (zh) * | 2008-08-01 | 2008-12-17 | 李翔 | 一种能修复眼部病变损伤改善视力疲劳的制剂及其制备方法 |
CA2836445C (fr) * | 2010-06-25 | 2019-06-11 | Global Healthcare Focus, Llc | Procedes de traitement de troubles optiques |
-
2010
- 2010-12-03 TN TNP2010000566A patent/TN2010000566A1/fr unknown
-
2011
- 2011-05-06 RU RU2013125146/15A patent/RU2602738C2/ru active
- 2011-05-06 CA CA2819628A patent/CA2819628C/fr active Active
- 2011-05-06 ES ES11724029T patent/ES2770410T3/es active Active
- 2011-05-06 CN CN201180066768.3A patent/CN103338758B/zh not_active Expired - Fee Related
- 2011-05-06 AU AU2011334617A patent/AU2011334617B2/en not_active Ceased
- 2011-05-06 WO PCT/IB2011/000960 patent/WO2012073077A1/fr active Application Filing
- 2011-05-06 US US13/991,286 patent/US20130317036A1/en not_active Abandoned
- 2011-05-06 EP EP11724029.1A patent/EP2646010B1/fr active Active
- 2011-05-06 PL PL11724029T patent/PL2646010T3/pl unknown
- 2011-05-06 JP JP2013541436A patent/JP5897592B2/ja not_active Expired - Fee Related
-
2013
- 2013-05-31 ZA ZA2013/04026A patent/ZA201304026B/en unknown
-
2015
- 2015-01-16 US US14/599,223 patent/US20150133455A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP5897592B2 (ja) | 2016-03-30 |
RU2013125146A (ru) | 2015-01-10 |
CN103338758B (zh) | 2017-12-12 |
CN103338758A (zh) | 2013-10-02 |
EP2646010A1 (fr) | 2013-10-09 |
AU2011334617A1 (en) | 2013-06-20 |
CA2819628C (fr) | 2019-12-03 |
JP2013544275A (ja) | 2013-12-12 |
US20150133455A1 (en) | 2015-05-14 |
ES2770410T3 (es) | 2020-07-01 |
RU2602738C2 (ru) | 2016-11-20 |
WO2012073077A1 (fr) | 2012-06-07 |
AU2011334617A2 (en) | 2013-08-01 |
ZA201304026B (en) | 2014-02-26 |
CA2819628A1 (fr) | 2012-06-07 |
US20130317036A1 (en) | 2013-11-28 |
AU2011334617B2 (en) | 2017-01-12 |
EP2646010B1 (fr) | 2019-11-13 |
PL2646010T3 (pl) | 2020-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TN2010000566A1 (en) | Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs | |
WO2012158910A3 (fr) | Compositions et méthodes pour le traitement de maladies de la rétine | |
WO2011151685A8 (fr) | N-acétyl-dl-leucine, médicament neuroprotecteur et rétinoprotecteur | |
MY171920A (en) | Prevention and treatment of ocular conditions | |
AU2016216625A1 (en) | Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency | |
MX361858B (es) | Formulación oftálmica de lípido polioxilo o de ácido graso polioxilo y tratamiento de padecimientos oculares. | |
MX351230B (es) | Formulacion oftalmica y metodo para mitigar la presbicia. | |
NZ631041A (en) | Opthalmic solution comprising diquafosol | |
WO2012170947A3 (fr) | Procédés pour moduler l'expression du facteur 12 | |
EP2401648A4 (fr) | Port de lentille d'orthokératologie combiné à un traitement chimique pour corriger la myopie, l'hypermétropie ou l'astigmatie | |
WO2012170945A3 (fr) | Procédés pour moduler l'expression de la kallicréine (klkb1) | |
WO2008094825A3 (fr) | Compositions et procédés destinés à maintenir, renforcer, améliorer ou favoriser la santé des yeux | |
AU2012366182A8 (en) | Method of treating diabetes using non-glycosylated apolipoprotein A-IV | |
WO2012099448A3 (fr) | Adénovirus recombinant exprimant le gène αa-cristallin et thérapie génique de la rétinopathie vasculaire l'utilisant | |
MX342930B (es) | Composicion reticuladora mejorada, suministrada por iontoforesis, util para el tratamiento de queratocono. | |
WO2011076368A3 (fr) | Formulation peptidique ophtalmique topique | |
AU2012207301A8 (en) | Apolipoprotein AIV as an antidiabetic peptide | |
IN2014MN01442A (fr) | ||
MX2012010520A (es) | Composicion antioxidante para reducir el estres oxidativo atribuible al tratamiento con farmacos anticonceptivos hormonales. | |
MX2013008635A (es) | Mejoras de y relacionadas con composiciones. | |
WO2013188876A3 (fr) | Procédés de modulation de l'expression de la kallikréine (klkb1) | |
WO2012105854A3 (fr) | Compositions pour administration oculaire | |
IN2012DN03631A (fr) | ||
Zheng | Nonarteritic anterior ischaemic optic neuropathy: case report | |
Galán et al. | Comparison between clinical results of two diffractive multifocal lenses with the same platform but different additions |